Newsroom | 5285 results

DUBLIN--(BUSINESS WIRE)--The "Diabetic Eye Disease Devices Market - Global Forecast 2025-2032" has been added to ResearchAndMarkets.com's offering. The Diabetic Eye Disease Devices Market is currently witnessing significant growth, expanding from USD 18.92 billion in 2024 to USD 20.81 billion in 2025, and projected to reach USD 40.42 billion by 2032 at a CAGR of 9.94%. Positioned at the forefront of technological advancements and increasing clinical demands, this market offers unique opportunit...

GENEVA--(BUSINESS WIRE)--Alcon Announces Amended Merger Agreement with STAAR Surgical...

DUBLIN--(BUSINESS WIRE)--The "Ocular Inflammation and Pain - Market Insights, Epidemiology, and Market Forecast - 2034" has been added to ResearchAndMarkets.com's offering. This report examines the landscape, offering detailed epidemiological data and patient demographics across major markets from 2020 to 2034. It highlights current treatment trends, unmet medical needs, and market potential, enabling stakeholders to make informed strategic decisions. The report covers diagnosis and treatment a...

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today announced that leading proxy advisory firm Egan-Jones Ratings Company (“Egan-Jones”) has reaffirmed its recommendation that shareholders vote “AGAINST” the proposed acquisition of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) by Alcon Inc. (“Alcon”) (NYSE: ALC) on the GREEN Proxy Card. Earlier today, the Company announced the completion of the belated, band-aid 30-day go-s...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the expiration of the previously announced go-shop period pursuant to STAAR’s amended merger agreement with Alcon Inc. (SIX/NYSE: ALC). The go-shop period expired at 11:59 p.m. Eastern Time on December 6, 2025. No proposals were received prior to the expiration. During the go-shop perio...

CHICAGO--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based Cellgorithm™ technology, which lays the groundwork for programmable control of gene activity in human stem cells and offers an alternative to the slow, variable manual processes researchers use today. In traditional cell differentiation, scientists expose stem cells to a serie...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company’s Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 171,900 shares of the company’s common stock to 3 new employees (the...

ALISO VIEJO, California--(BUSINESS WIRE)--ViaLase, Inc., azienda di tecnologia medica in fase clinica all'avanguardia nelle soluzioni laser senza incisione per il glaucoma, ha annunciato oggi il trattamento del primo paziente nell'ambito della sperimentazione clinica IDE (Investigational Device Exemption) negli Stati Uniti, volta a valutare la procedura di trabeculotomia laser a femtosecondi dell'azienda per la gestione del glaucoma, una malattia progressiva e incurabile permanente che rimane u...

ALISO VIEJO, California--(BUSINESS WIRE)--ViaLase, Inc., una empresa de tecnología médica en fase clínica que se especializa en el desarrollo de soluciones láser no invasivas para el glaucoma, anunció hoy que se ha tratado al primer paciente en su ensayo clínico estadounidense con exención de dispositivos en investigación (IDE, por sus siglas en inglés), que evalúa el procedimiento de trabeculotomía con láser de femtosegundo de la empresa para el tratamiento del glaucoma, una enfermedad crónica...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--ViaLase, Inc., een medisch technologiebedrijf in de klinische fase dat baanbrekend werk verricht op het gebied van incisie-vrije, lasergebaseerde oplossingen voor glaucoom, heeft vandaag bekendgemaakt dat de eerste patiënt is behandeld in het kader van zijn klinisch onderzoek met vrijstelling voor onderzoeksapparatuur (IDE) in de VS. Met deze oplossing wordt de femtosecond-lasertrabeculotomieprocedure van het bedrijf geëvalueerd voor de behandeling van glau...